{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:33Z","timestamp":1790960553524,"version":"4.1.0"},"reference-count":22,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9\u2005mg twice daily and 18\u2005mg twice daily (hereafter nerandomilast 9\u2005mg and 18\u2005mg, respectively) reduced the decline in forced vital capacity at week 52 compared with placebo (primary end-point). We assessed the effects of nerandomilast up to the final database lock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Time to first acute exacerbation of interstitial lung disease, hospitalisation for respiratory cause or death (key secondary end-point) and other time-to-event end-points were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At the final database lock, the mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      exposure to trial medication was 15.1\u00b15.7\u2005months and the mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      observation period was 17.0\u00b14.1\u2005months. Compared with placebo, the hazard ratio for the key secondary end-point was 0.78 (95% CI 0.61\u20131.00) for nerandomilast 9\u2005mg and 0.77 (95% CI 0.60\u20130.99) for nerandomilast 18\u2005mg; hazard ratios were lower among patients not taking nintedanib (0.69 (95% CI 0.49\u20130.97) and 0.65 (95% CI 0.46\u20130.92), respectively) than among those taking background nintedanib (0.90 (95% CI 0.63\u20131.30) and 0.93 (95% CI 0.65\u20131.34), respectively). For death, the hazard ratio\n                      <jats:italic>versus<\/jats:italic>\n                      placebo was 0.51 (95% CI 0.34\u20130.78) for both nerandomilast doses. Adverse events led to discontinuation of trial medication in 12.5%, 12.0% and 12.3% of the placebo, nerandomilast 9\u2005mg and nerandomilast 18\u2005mg groups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01899-2025","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:20:23Z","timestamp":1774545623000},"page":"2501899","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial"],"prefix":"10.1183","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-6962","authenticated-orcid":false,"given":"Marlies S.","family":"Wijsenbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-9978","authenticated-orcid":false,"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9966","authenticated-orcid":false,"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8594-1448","authenticated-orcid":false,"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-6290","authenticated-orcid":false,"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FIBRONEER-ILD Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026070907350747000_68.1.2501899.1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.3669"},{"key":"2026070907350747000_68.1.2501899.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026070907350747000_68.1.2501899.3","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202205-0910LE"},{"key":"2026070907350747000_68.1.2501899.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"2026070907350747000_68.1.2501899.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026070907350747000_68.1.2501899.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00215-6"},{"key":"2026070907350747000_68.1.2501899.7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-024-00778-z","article-title":"Continued treatment with nintedanib in patients with progressive pulmonary fibrosis: data from INBUILD-ON","volume":"203","author":"Wuyts","year":"2025","journal-title":"Lung"},{"key":"2026070907350747000_68.1.2501899.8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12890-024-03247-8","article-title":"Design and baseline characteristics of the ILD-PRO Registry in patients with progressive pulmonary fibrosis","volume":"24","author":"Lobo","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026070907350747000_68.1.2501899.9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449"},{"key":"2026070907350747000_68.1.2501899.10","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17303"},{"key":"2026070907350747000_68.1.2501899.11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1165\/rcmb.2024-0614OC","article-title":"Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast","volume":"73","author":"Reininger","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026070907350747000_68.1.2501899.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"},{"key":"2026070907350747000_68.1.2501899.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503643"},{"key":"2026070907350747000_68.1.2501899.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2026070907350747000_68.1.2501899.15","doi-asserted-by":"publisher","DOI":"10.1080\/01926230500385549"},{"key":"2026070907350747000_68.1.2501899.16","unstructured":"Amgen Inc . OTEZLA (apremilast) prescribing information. 2024. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/205437Orig1s013correctedlbl.pdf Date last accessed: 22 February 2026."},{"key":"2026070907350747000_68.1.2501899.17","unstructured":"AstraZeneca . DALIRESP (roflumilast) prescribing information. 2018. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf Date last accessed: 22 February 2026."},{"key":"2026070907350747000_68.1.2501899.18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/resp.14579","article-title":"Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis","volume":"28","author":"Maher","year":"2023","journal-title":"Respirology"},{"key":"2026070907350747000_68.1.2501899.19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.chest.2025.02.018","article-title":"Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis","volume":"168","author":"Oldham","year":"2025","journal-title":"Chest"},{"key":"2026070907350747000_68.1.2501899.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500526"},{"key":"2026070907350747000_68.1.2501899.21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis","volume":"18","author":"Dempsey","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026070907350747000_68.1.2501899.22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","article-title":"A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"40","author":"Podolanczuk","year":"2023","journal-title":"Adv Ther"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01899-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:35:15Z","timestamp":1783607715000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01899-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/13993003.01899-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01899-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}